ArticleBMC cancer2025
Factors influencing clinical decision-making and health-related quality of life changes in colorectal cancer patients receiving targeted therapy: a multicenter study in China.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Latent profiles and influencing factors of quality of life among patients with colorectal cancer and an enterostomy in Southwest China: A multicenter cross-sectional study.Asia-Pacific journal of oncology nursing · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this paper is to assess the current clinical application of targeted therapy in colorectal cancer (CRC), identify factors influencing patients' acceptance of targeted therapy, and evaluate its impact of targeted therapy on patients' health-related quality of life (HRQoL).
methodsThis study was based on a national multi-center survey. From March 2020 to March 2021, involved 19 tertiary hospitals across seven regions in China through multi-stage stratified sampling. CRC patients who underwent genetic testing participated. Data on demographic and clinical characteristics, disease knowledge, medical service utilization, medical expenditure, and HRQoL before and after treatment were collected through face-to-face interviews. Logistic regression identified factors affecting therapy acceptance, while the HRQoL changes in pre-and post-treatment were compared by the Mann-Whitney U test.
resultsAmong 1,468 eligible patients, 79.7% were aged 50+, 60% male, and 31.5% retired. Secondary education was the most common level (30.3%). A total of 62.7% of patients received targeted therapy. Multivariable analysis showed that metastasis at diagnosis, out-of-pocket expenses, and reimbursement ratio were positively associated with targeted therapy (P < 0.05), while initial diagnosis stage, region, and genetic testing reimbursement were negatively associated (P < 0.05). Post-therapy, patients' quality of life declined significantly (P < 0.001), especially in fatigue and financial burden.
conclusionsOur study revealed multiple factors influencing CRC patients' acceptance of targeted therapy and found that targeted therapy may adversely affect HRQoL. These findings emphasize the necessity of implementing more comprehensive patient management strategies to optimize the clinical application of targeted therapy and improve patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.